You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0231 The effect of “triple therapy” with anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins on the mortality of catastrophic antiphospholipid syndrome (CAPS) patients

Article Text

Article menu

Download PDFPDF

Oral Presentations
New treatments in SLE, Sjögren's and APS
OP0231 The effect of “triple therapy” with anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins on the mortality of catastrophic antiphospholipid syndrome (CAPS) patients
Free
  1. I Rodríguez-Pintό1,
  2. G Espinosa1,
  3. D Erkan2,
  4. Y Shoenfeld3,
  5. R Cervera1,
  6. on behalf of CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies)
  1. 1Department of Autoinmune Disease, Hospital Clínic, Barcelona, Spain
  2. 2Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, United States
  3. 3Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel

Abstract

Background Triple therapy (anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins) is empirically prescribed for the management of catastrophic antiphospholipid syndrome (CAPS). However, previous analyses have been inconsistent regarding the beneficial effect of triple therapy on patients' survival.

Objectives The objective of this study was to assess the effect that triple therapy has on the mortality risk of CAPS patients.

Methods In a cohort including 525 episodes of CAPS (CAPS Registry), we evaluated the relationship between triple therapy and mortality. Patients were grouped in three based on their treatments: a) triple therapy (anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins); b) drugs included in the triple therapy but in different combinations; c) none of the treatments included in the triple therapy. The primary endpoint was all-cause mortality. Multivariate logistic regression models were used to compare mortality risk between groups taking into account a set of possible confounding variables.

Results The “CAPS registry” cohort included 525 episodes of CAPS accounting for 502 patients. After excluding 38 episodes (7.2%), a total of 487 episodes of CAPS accounting for 471 patients (mean age 38 years; 67.9% female; primary APS patients 68.8%) were analyzed. Overall, 177 (36.3%) patients died. Triple therapy was prescribed in 197 episodes (40.5%), other combinations in 278 (57.1%), and none of those treatments in 12 episodes (2.5%). According to these three groups, mortality rate increased up to 27.9%, 40.6%, and 75%, respectively. Triple therapy was positively associated with a higher chance of survival when compared to non-treatment (adjusted odds ratio [OR]: 7.7 95%; confidence interval [95CI] 2.0–29.7) or to treatment with other combinations of drugs included in the triple therapy (adjusted OR 6.8; 95CI 1.7–26.9). Triple therapy accounted for a 64% decrease of the risk of death in patients with CAPS that received this combination of drugs.

Conclusions Triple therapy is independently associated to a higher survival rate among CAPS.

Acknowledgements To the CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies).

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2017-eular.3412

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.